SynsoryBio
SynsoryBio builds protein drugs with built-in if-then logic: they stay switched off until they sense they are in diseased tissue, which could make very potent cancer drugs safe enough to use.
Overview
SynsoryBio is creating conditionally activated protein therapeutics that sense their location in the body and become active only at diseased tissue, a way to widen the therapeutic window of potent immune agonists and cytotoxic biologics in cancer and autoimmune disease. The approach is related to masked or protease-activated biologics. The company is tagged oncology in the YC directory and is preclinical with a very small team; no sourced financing rounds are recorded.
Funding
All startupsPages like this
not linked directly; found by shared links- CompanyGranza Bio
Shares Cytokines & engineered cytokines, Y Combinator and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyLiyfe
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyREPROSENT
Shares Y Combinator and the tag yc.
- CompanyAlixia
Shares Y Combinator and the tag yc.
- CompanyVelorum Therapeutics
Shares Y Combinator and the tag yc.
- CompanyDelee
Shares Y Combinator and the tag yc.